aluates Reports

$ 0.0

Automative

Global Recombinant Insulin Analogue Market Research Report 2024

Published Date: July 2024

Report Code: QYRE-Auto-5Z15519

Global Recombinant Insulin Analogue Market Research Report 2023

BUY CHAPTERS

Global Recombinant Insulin Analogue Market Research Report 2024

Code: QYRE-Auto-5Z15519

Report

July 2024

Pages:85

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Novo Nordisk A S

Sanofi

The United Laboratories International Holdings Limited

Tonghua Dongbao Pharmaceutical Co., Ltd.

Gan & Lee Pharmaceuticals Co., Ltd

Recombinant Insulin Analogue Market

Recombinant insulin analogues are not easy to cause heterogenous allergic reaction in patients, with small side effects; It can simulate the physiological insulin secretion curve of human body, accurately adjust the blood glucose concentration of human body, reduce the risk of hypoglycemia, and further improve the safety and effectiveness.

The global Recombinant Insulin Analogue market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

North American market for Recombinant Insulin Analogue is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Recombinant Insulin Analogue is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global manufacturers of Recombinant Insulin Analogue include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Gan & Lee Pharmaceuticals Co., Ltd, The United Laboratories International Holdings Limited and Tonghua Dongbao Pharmaceutical Co., Ltd, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Recombinant Insulin Analogue, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Insulin Analogue.

Report Scope

The Recombinant Insulin Analogue market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Insulin Analogue market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Recombinant Insulin Analogue manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Recombinant Insulin Analogue Market Report

Report Metric	Details
Report Name	Recombinant Insulin Analogue Market
Segment by Type	Quick-Acting Medium Effect Long-Lasting Super Long-Acting
Segment by Application	Type 1 Diabetes Type 2 Diabetes
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Gan & Lee Pharmaceuticals Co., Ltd, The United Laboratories International Holdings Limited, Tonghua Dongbao Pharmaceutical Co., Ltd
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Insulin Analogue manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Insulin Analogue in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Recombinant Insulin Analogue Market report?

Ans: The main players in the Recombinant Insulin Analogue Market are Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Gan & Lee Pharmaceuticals Co., Ltd, The United Laboratories International Holdings Limited, Tonghua Dongbao Pharmaceutical Co., Ltd

What are the Application segmentation covered in the Recombinant Insulin Analogue Market report?

Ans: The Applications covered in the Recombinant Insulin Analogue Market report are Type 1 Diabetes, Type 2 Diabetes

What are the Type segmentation covered in the Recombinant Insulin Analogue Market report?

Ans: The Types covered in the Recombinant Insulin Analogue Market report are Quick-Acting, Medium Effect, Long-Lasting, Super Long-Acting

1 Recombinant Insulin Analogue Market Overview

1.1 Product Overview and Scope of Recombinant Insulin Analogue

1.2 Recombinant Insulin Analogue Segment by Type

1.2.1 Global Recombinant Insulin Analogue Market Value Comparison by Type (2024-2030)

1.2.2 Quick-Acting

1.2.3 Medium Effect

1.2.4 Long-Lasting

1.2.5 Super Long-Acting

1.3 Recombinant Insulin Analogue Segment by Application

1.3.1 Global Recombinant Insulin Analogue Market Value by Application: (2024-2030)

1.3.2 Type 1 Diabetes

1.3.3 Type 2 Diabetes

1.4 Global Recombinant Insulin Analogue Market Size Estimates and Forecasts

1.4.1 Global Recombinant Insulin Analogue Revenue 2019-2030

1.4.2 Global Recombinant Insulin Analogue Sales 2019-2030

1.4.3 Global Recombinant Insulin Analogue Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Recombinant Insulin Analogue Market Competition by Manufacturers

2.1 Global Recombinant Insulin Analogue Sales Market Share by Manufacturers (2019-2024)

2.2 Global Recombinant Insulin Analogue Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Recombinant Insulin Analogue Average Price by Manufacturers (2019-2024)

2.4 Global Recombinant Insulin Analogue Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Recombinant Insulin Analogue, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Recombinant Insulin Analogue, Product Type & Application

2.7 Recombinant Insulin Analogue Market Competitive Situation and Trends

2.7.1 Recombinant Insulin Analogue Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Recombinant Insulin Analogue Players Market Share by Revenue

2.7.3 Global Recombinant Insulin Analogue Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Recombinant Insulin Analogue Retrospective Market Scenario by Region

3.1 Global Recombinant Insulin Analogue Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Recombinant Insulin Analogue Global Recombinant Insulin Analogue Sales by Region: 2019-2030

3.2.1 Global Recombinant Insulin Analogue Sales by Region: 2019-2024

3.2.2 Global Recombinant Insulin Analogue Sales by Region: 2025-2030

3.3 Global Recombinant Insulin Analogue Global Recombinant Insulin Analogue Revenue by Region: 2019-2030

3.3.1 Global Recombinant Insulin Analogue Revenue by Region: 2019-2024

3.3.2 Global Recombinant Insulin Analogue Revenue by Region: 2025-2030

3.4 North America Recombinant Insulin Analogue Market Facts & Figures by Country

3.4.1 North America Recombinant Insulin Analogue Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Recombinant Insulin Analogue Sales by Country (2019-2030)

3.4.3 North America Recombinant Insulin Analogue Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Recombinant Insulin Analogue Market Facts & Figures by Country

3.5.1 Europe Recombinant Insulin Analogue Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Recombinant Insulin Analogue Sales by Country (2019-2030)

3.5.3 Europe Recombinant Insulin Analogue Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Recombinant Insulin Analogue Market Facts & Figures by Country

3.6.1 Asia Pacific Recombinant Insulin Analogue Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Recombinant Insulin Analogue Sales by Country (2019-2030)

3.6.3 Asia Pacific Recombinant Insulin Analogue Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Recombinant Insulin Analogue Market Facts & Figures by Country

3.7.1 Latin America Recombinant Insulin Analogue Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Recombinant Insulin Analogue Sales by Country (2019-2030)

3.7.3 Latin America Recombinant Insulin Analogue Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Recombinant Insulin Analogue Market Facts & Figures by Country

3.8.1 Middle East and Africa Recombinant Insulin Analogue Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Recombinant Insulin Analogue Sales by Country (2019-2030)

3.8.3 Middle East and Africa Recombinant Insulin Analogue Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Recombinant Insulin Analogue Sales by Type (2019-2030)

4.1.1 Global Recombinant Insulin Analogue Sales by Type (2019-2024)

4.1.2 Global Recombinant Insulin Analogue Sales by Type (2025-2030)

4.1.3 Global Recombinant Insulin Analogue Sales Market Share by Type (2019-2030)

4.2 Global Recombinant Insulin Analogue Revenue by Type (2019-2030)

4.2.1 Global Recombinant Insulin Analogue Revenue by Type (2019-2024)

4.2.2 Global Recombinant Insulin Analogue Revenue by Type (2025-2030)

4.2.3 Global Recombinant Insulin Analogue Revenue Market Share by Type (2019-2030)

4.3 Global Recombinant Insulin Analogue Price by Type (2019-2030)

5 Segment by Application

5.1 Global Recombinant Insulin Analogue Sales by Application (2019-2030)

5.1.1 Global Recombinant Insulin Analogue Sales by Application (2019-2024)

5.1.2 Global Recombinant Insulin Analogue Sales by Application (2025-2030)

5.1.3 Global Recombinant Insulin Analogue Sales Market Share by Application (2019-2030)

5.2 Global Recombinant Insulin Analogue Revenue by Application (2019-2030)

5.2.1 Global Recombinant Insulin Analogue Revenue by Application (2019-2024)

5.2.2 Global Recombinant Insulin Analogue Revenue by Application (2025-2030)

5.2.3 Global Recombinant Insulin Analogue Revenue Market Share by Application (2019-2030)

5.3 Global Recombinant Insulin Analogue Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Novo Nordisk A/S

6.1.1 Novo Nordisk A/S Corporation Information

6.1.2 Novo Nordisk A/S Description and Business Overview

6.1.3 Novo Nordisk A/S Recombinant Insulin Analogue Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Novo Nordisk A/S Recombinant Insulin Analogue Product Portfolio

6.1.5 Novo Nordisk A/S Recent Developments/Updates

6.2 Eli Lilly and Company

6.2.1 Eli Lilly and Company Corporation Information

6.2.2 Eli Lilly and Company Description and Business Overview

6.2.3 Eli Lilly and Company Recombinant Insulin Analogue Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Eli Lilly and Company Recombinant Insulin Analogue Product Portfolio

6.2.5 Eli Lilly and Company Recent Developments/Updates

6.3 Sanofi

6.3.1 Sanofi Corporation Information

6.3.2 Sanofi Description and Business Overview

6.3.3 Sanofi Recombinant Insulin Analogue Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Sanofi Recombinant Insulin Analogue Product Portfolio

6.3.5 Sanofi Recent Developments/Updates

6.4 Gan & Lee Pharmaceuticals Co., Ltd

6.4.1 Gan & Lee Pharmaceuticals Co., Ltd Corporation Information

6.4.2 Gan & Lee Pharmaceuticals Co., Ltd Description and Business Overview

6.4.3 Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Product Portfolio

6.4.5 Gan & Lee Pharmaceuticals Co., Ltd Recent Developments/Updates

6.5 The United Laboratories International Holdings Limited

6.5.1 The United Laboratories International Holdings Limited Corporation Information

6.5.2 The United Laboratories International Holdings Limited Description and Business Overview

6.5.3 The United Laboratories International Holdings Limited Recombinant Insulin Analogue Sales, Revenue and Gross Margin (2019-2024)

6.5.4 The United Laboratories International Holdings Limited Recombinant Insulin Analogue Product Portfolio

6.5.5 The United Laboratories International Holdings Limited Recent Developments/Updates

6.6 Tonghua Dongbao Pharmaceutical Co., Ltd

6.6.1 Tonghua Dongbao Pharmaceutical Co., Ltd Corporation Information

6.6.2 Tonghua Dongbao Pharmaceutical Co., Ltd Description and Business Overview

6.6.3 Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Product Portfolio

6.6.5 Tonghua Dongbao Pharmaceutical Co., Ltd Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Recombinant Insulin Analogue Industry Chain Analysis

7.2 Recombinant Insulin Analogue Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Recombinant Insulin Analogue Production Mode & Process

7.4 Recombinant Insulin Analogue Sales and Marketing

7.4.1 Recombinant Insulin Analogue Sales Channels

7.4.2 Recombinant Insulin Analogue Distributors

7.5 Recombinant Insulin Analogue Customers

8 Recombinant Insulin Analogue Market Dynamics

8.1 Recombinant Insulin Analogue Industry Trends

8.2 Recombinant Insulin Analogue Market Drivers

8.3 Recombinant Insulin Analogue Market Challenges

8.4 Recombinant Insulin Analogue Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Novo Nordisk A S

Sanofi

The United Laboratories International Holdings Limited

Tonghua Dongbao Pharmaceutical Co., Ltd.

Gan & Lee Pharmaceuticals Co., Ltd

List of Tables

Table 1. Global Recombinant Insulin Analogue Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Recombinant Insulin Analogue Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Recombinant Insulin Analogue Market Competitive Situation by Manufacturers in 2023

Table 4. Global Recombinant Insulin Analogue Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Recombinant Insulin Analogue Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Recombinant Insulin Analogue Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Recombinant Insulin Analogue Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Recombinant Insulin Analogue Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Recombinant Insulin Analogue, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Recombinant Insulin Analogue, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Recombinant Insulin Analogue, Product Type & Application

Table 12. Global Key Manufacturers of Recombinant Insulin Analogue, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Recombinant Insulin Analogue by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Insulin Analogue as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Recombinant Insulin Analogue Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Recombinant Insulin Analogue Sales by Region (2019-2024) & (K Units)

Table 18. Global Recombinant Insulin Analogue Sales Market Share by Region (2019-2024)

Table 19. Global Recombinant Insulin Analogue Sales by Region (2025-2030) & (K Units)

Table 20. Global Recombinant Insulin Analogue Sales Market Share by Region (2025-2030)

Table 21. Global Recombinant Insulin Analogue Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Recombinant Insulin Analogue Revenue Market Share by Region (2019-2024)

Table 23. Global Recombinant Insulin Analogue Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Recombinant Insulin Analogue Revenue Market Share by Region (2025-2030)

Table 25. North America Recombinant Insulin Analogue Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Recombinant Insulin Analogue Sales by Country (2019-2024) & (K Units)

Table 27. North America Recombinant Insulin Analogue Sales by Country (2025-2030) & (K Units)

Table 28. North America Recombinant Insulin Analogue Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Recombinant Insulin Analogue Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Recombinant Insulin Analogue Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Recombinant Insulin Analogue Sales by Country (2019-2024) & (K Units)

Table 32. Europe Recombinant Insulin Analogue Sales by Country (2025-2030) & (K Units)

Table 33. Europe Recombinant Insulin Analogue Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Recombinant Insulin Analogue Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Recombinant Insulin Analogue Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Recombinant Insulin Analogue Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Recombinant Insulin Analogue Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Recombinant Insulin Analogue Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Recombinant Insulin Analogue Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Recombinant Insulin Analogue Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Recombinant Insulin Analogue Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Recombinant Insulin Analogue Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Recombinant Insulin Analogue Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Recombinant Insulin Analogue Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Recombinant Insulin Analogue Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Recombinant Insulin Analogue Sales by Country (2019-2024) & (K Units)

Table 47. Middle East & Africa Recombinant Insulin Analogue Sales by Country (2025-2030) & (K Units)

Table 48. Middle East & Africa Recombinant Insulin Analogue Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Recombinant Insulin Analogue Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Recombinant Insulin Analogue Sales (K Units) by Type (2019-2024)

Table 51. Global Recombinant Insulin Analogue Sales (K Units) by Type (2025-2030)

Table 52. Global Recombinant Insulin Analogue Sales Market Share by Type (2019-2024)

Table 53. Global Recombinant Insulin Analogue Sales Market Share by Type (2025-2030)

Table 54. Global Recombinant Insulin Analogue Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Recombinant Insulin Analogue Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Recombinant Insulin Analogue Revenue Market Share by Type (2019-2024)

Table 57. Global Recombinant Insulin Analogue Revenue Market Share by Type (2025-2030)

Table 58. Global Recombinant Insulin Analogue Price (US$/Unit) by Type (2019-2024)

Table 59. Global Recombinant Insulin Analogue Price (US$/Unit) by Type (2025-2030)

Table 60. Global Recombinant Insulin Analogue Sales (K Units) by Application (2019-2024)

Table 61. Global Recombinant Insulin Analogue Sales (K Units) by Application (2025-2030)

Table 62. Global Recombinant Insulin Analogue Sales Market Share by Application (2019-2024)

Table 63. Global Recombinant Insulin Analogue Sales Market Share by Application (2025-2030)

Table 64. Global Recombinant Insulin Analogue Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Recombinant Insulin Analogue Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Recombinant Insulin Analogue Revenue Market Share by Application (2019-2024)

Table 67. Global Recombinant Insulin Analogue Revenue Market Share by Application (2025-2030)

Table 68. Global Recombinant Insulin Analogue Price (US$/Unit) by Application (2019-2024)

Table 69. Global Recombinant Insulin Analogue Price (US$/Unit) by Application (2025-2030)

Table 70. Novo Nordisk A/S Corporation Information

Table 71. Novo Nordisk A/S Description and Business Overview

Table 72. Novo Nordisk A/S Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Novo Nordisk A/S Recombinant Insulin Analogue Product

Table 74. Novo Nordisk A/S Recent Developments/Updates

Table 75. Eli Lilly and Company Corporation Information

Table 76. Eli Lilly and Company Description and Business Overview

Table 77. Eli Lilly and Company Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. Eli Lilly and Company Recombinant Insulin Analogue Product

Table 79. Eli Lilly and Company Recent Developments/Updates

Table 80. Sanofi Corporation Information

Table 81. Sanofi Description and Business Overview

Table 82. Sanofi Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Sanofi Recombinant Insulin Analogue Product

Table 84. Sanofi Recent Developments/Updates

Table 85. Gan & Lee Pharmaceuticals Co., Ltd Corporation Information

Table 86. Gan & Lee Pharmaceuticals Co., Ltd Description and Business Overview

Table 87. Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Product

Table 89. Gan & Lee Pharmaceuticals Co., Ltd Recent Developments/Updates

Table 90. The United Laboratories International Holdings Limited Corporation Information

Table 91. The United Laboratories International Holdings Limited Description and Business Overview

Table 92. The United Laboratories International Holdings Limited Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. The United Laboratories International Holdings Limited Recombinant Insulin Analogue Product

Table 94. The United Laboratories International Holdings Limited Recent Developments/Updates

Table 95. Tonghua Dongbao Pharmaceutical Co., Ltd Corporation Information

Table 96. Tonghua Dongbao Pharmaceutical Co., Ltd Description and Business Overview

Table 97. Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Product

Table 99. Tonghua Dongbao Pharmaceutical Co., Ltd Recent Developments/Updates

Table 100. Key Raw Materials Lists

Table 101. Raw Materials Key Suppliers Lists

Table 102. Recombinant Insulin Analogue Distributors List

Table 103. Recombinant Insulin Analogue Customers List

Table 104. Recombinant Insulin Analogue Market Trends

Table 105. Recombinant Insulin Analogue Market Drivers

Table 106. Recombinant Insulin Analogue Market Challenges

Table 107. Recombinant Insulin Analogue Market Restraints

Table 108. Research Programs/Design for This Report

Table 109. Key Data Information from Secondary Sources

Table 110. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Recombinant Insulin Analogue

Figure 2. Global Recombinant Insulin Analogue Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Recombinant Insulin Analogue Market Share by Type in 2023 & 2030

Figure 4. Quick-Acting Product Picture

Figure 5. Medium Effect Product Picture

Figure 6. Long-Lasting Product Picture

Figure 7. Super Long-Acting Product Picture

Figure 8. Global Recombinant Insulin Analogue Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 9. Global Recombinant Insulin Analogue Market Share by Application in 2023 & 2030

Figure 10. Type 1 Diabetes

Figure 11. Type 2 Diabetes

Figure 12. Global Recombinant Insulin Analogue Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Recombinant Insulin Analogue Market Size (2019-2030) & (US$ Million)

Figure 14. Global Recombinant Insulin Analogue Sales (2019-2030) & (K Units)

Figure 15. Global Recombinant Insulin Analogue Average Price (US$/Unit) & (2019-2030)

Figure 16. Recombinant Insulin Analogue Report Years Considered

Figure 17. Recombinant Insulin Analogue Sales Share by Manufacturers in 2023

Figure 18. Global Recombinant Insulin Analogue Revenue Share by Manufacturers in 2023

Figure 19. The Global 5 and 10 Largest Recombinant Insulin Analogue Players: Market Share by Revenue in 2023

Figure 20. Recombinant Insulin Analogue Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 21. Global Recombinant Insulin Analogue Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 22. North America Recombinant Insulin Analogue Sales Market Share by Country (2019-2030)

Figure 23. North America Recombinant Insulin Analogue Revenue Market Share by Country (2019-2030)

Figure 24. United States Recombinant Insulin Analogue Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 25. Canada Recombinant Insulin Analogue Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 26. Europe Recombinant Insulin Analogue Sales Market Share by Country (2019-2030)

Figure 27. Europe Recombinant Insulin Analogue Revenue Market Share by Country (2019-2030)

Figure 28. Germany Recombinant Insulin Analogue Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. France Recombinant Insulin Analogue Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. U.K. Recombinant Insulin Analogue Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Italy Recombinant Insulin Analogue Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Russia Recombinant Insulin Analogue Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Asia Pacific Recombinant Insulin Analogue Sales Market Share by Region (2019-2030)

Figure 34. Asia Pacific Recombinant Insulin Analogue Revenue Market Share by Region (2019-2030)

Figure 35. China Recombinant Insulin Analogue Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. Japan Recombinant Insulin Analogue Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. South Korea Recombinant Insulin Analogue Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. India Recombinant Insulin Analogue Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Australia Recombinant Insulin Analogue Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. China Taiwan Recombinant Insulin Analogue Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Southeast Asia Recombinant Insulin Analogue Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Latin America Recombinant Insulin Analogue Sales Market Share by Country (2019-2030)

Figure 43. Latin America Recombinant Insulin Analogue Revenue Market Share by Country (2019-2030)

Figure 44. Mexico Recombinant Insulin Analogue Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Brazil Recombinant Insulin Analogue Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Argentina Recombinant Insulin Analogue Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Middle East & Africa Recombinant Insulin Analogue Sales Market Share by Country (2019-2030)

Figure 48. Middle East & Africa Recombinant Insulin Analogue Revenue Market Share by Country (2019-2030)

Figure 49. Turkey Recombinant Insulin Analogue Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Saudi Arabia Recombinant Insulin Analogue Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. UAE Recombinant Insulin Analogue Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. Global Sales Market Share of Recombinant Insulin Analogue by Type (2019-2030)

Figure 53. Global Revenue Market Share of Recombinant Insulin Analogue by Type (2019-2030)

Figure 54. Global Recombinant Insulin Analogue Price (US$/Unit) by Type (2019-2030)

Figure 55. Global Sales Market Share of Recombinant Insulin Analogue by Application (2019-2030)

Figure 56. Global Revenue Market Share of Recombinant Insulin Analogue by Application (2019-2030)

Figure 57. Global Recombinant Insulin Analogue Price (US$/Unit) by Application (2019-2030)

Figure 58. Recombinant Insulin Analogue Value Chain

Figure 59. Recombinant Insulin Analogue Production Process

Figure 60. Channels of Distribution (Direct Vs Distribution)

Figure 61. Distributors Profiles

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Recombinant Human Insulin Market Insights Forecast to 2030

Global Mixed Recombinant Human Insulin Injection Market Research Report 2024

Global Human Insulin Market Research Report 2024

Global Insulin Analog Market Research Report 2025

Global Insulin Detemir Injection Market Research Report 2024

Global Insulin API Market Insights Forecast to 2030

Global Long Acting Insulin Analogue Market Research Report 2025

Global Insulin Raw Material Market Research Report 2025

Global Premixed Human Insulin Market Research Report 2024

Global Human Insulin Regular Market Research Report 2025

Global Oral Insulin Market Research Report 2025

Global Fast Acting Insulin Analog Market Research Report 2025

Global Insulin Preparation Market Research Report 2025

Global Recombinant Hormone Market Research Report 2024

Global Insulin Drugs for Diabetes Market Research Report 2024

Global Recombinant Insulin Lispro Injection Market Research Report 2024

Global Recombinant Growth Hormone Market Research Report 2024

Global Insulin Storage Devices Market Research Report 2024

Global Synthetic Peptides for Type 2 Diabetes Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions